Crinetics Pharmaceuticals, Inc.
CRNX
$84.69
0Crinetics Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for rare endocrine diseases and endocrine-related tumors, with its lead product Palsonify (paltusotine) approved for acromegaly. The company is a niche player in the endocrine space, leveraging its expertise in oral small-molecule therapies to address underserved conditions. The current investor narrative centers on the transformative acquisition by Vertex Pharmaceuticals, announced in July 2026, which values Crinetics at $10 billion and has driven a massive re-rating of the stock. The deal highlights the strategic value of Crinetics' commercial product and pipeline, including atumelnant for congenital adrenal hyperplasia, and has sparked debate about the fairness of the premium and the long-term growth potential under Vertex's ownership.…
CRNX
Crinetics Pharmaceuticals, Inc.
$84.69
Related headlines
Investment Opinion: Should I buy CRNX Today?
Based on the analysis, the recommendation is a Hold. The stock is trading near its acquisition price, with limited upside to the average analyst target of $85.50 (0.96% upside). The consensus rating is 'hold' with a mean score of 2.86, reflecting caution. The thesis is that the acquisition provides a floor, but the premium valuation and lack of near-term catalysts limit appreciation potential.
Sign up to view all
CRNX 12-Month Price Forecast
The AI assessment is neutral, reflecting the balanced risk-reward profile. The acquisition provides a clear floor, but the valuation is stretched, and upside is limited. The stock is likely to trade near the deal price unless new catalysts emerge. Upgrades to bullish would require evidence of accelerating revenue growth or successful pipeline milestones, while downgrades to bearish would occur if the deal fails or commercial execution disappoints.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Crinetics Pharmaceuticals, Inc.'s 12-month outlook, with a consensus price target around $85.50 and implied upside of +1.0% versus the current price.
Average Target
$85.50
0 analysts
Implied Upside
+1.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$85 - $90
Analyst target range
Analyst coverage includes 10 analysts, with a consensus recommendation of 'hold' and a mean rating of 2.86 (where 1 is strong buy and 5 is sell). The average target price is $85.50, implying a modest 0.96% upside from the current price of $84.69. The target range is narrow, from $85.00 to $90.00, indicating relatively high conviction among analysts, though the recent downgrades to 'hold' suggest caution following the acquisition announcement. The high target of $90.00 assumes successful integration and revenue growth from Palsonify and pipeline assets, while the low target of $85.00 likely reflects the deal price of $10 billion, which translates to approximately $85 per share, limiting upside potential. The recent downgrades by multiple firms (e.g., TD Cowen, Jefferies) from 'buy' to 'hold' signal that the stock is fairly valued near the acquisition price, with limited room for further appreciation.
Bulls vs Bears: CRNX Investment Factors
Crinetics presents a compelling bull case driven by the transformative Vertex acquisition, strong revenue growth from Palsonify, and a solid balance sheet. However, the bear case highlights an extreme valuation, deep unprofitability, and limited upside to analyst targets. Currently, the bull case has stronger evidence due to the acquisition premium and strategic validation, but the key tension is whether the market's high expectations for future revenue growth are justified. If Palsonify and pipeline assets deliver strong sales under Vertex, the stock could appreciate; otherwise, the valuation could compress significantly. The most critical factor is the successful completion of the acquisition and the subsequent execution of growth plans.
Bullish
- Transformative acquisition by Vertex at $10B: Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion, representing a 102% premium to the pre-announcement price. This validates the strategic value of Crinetics' commercial product Palsonify and pipeline, including atumelnant for congenital adrenal hyperplasia, and provides a clear floor for the stock price.
- Strong revenue growth from Palsonify: Q1 2026 revenue grew 28.7% year-over-year to $10.7 million, driven by Palsonify sales of $10.3 million. This demonstrates commercial traction for the lead product, which is crucial for future growth under Vertex's ownership.
- High gross margin of 98.1%: Crinetics' gross margin is exceptionally high at 98.1%, reflecting the low cost of goods for its oral small-molecule drug. This indicates strong unit economics that can scale profitably as revenue grows.
- Solid balance sheet with minimal debt: The company has a current ratio of 12.3 and a debt-to-equity ratio of 0.05, indicating strong liquidity and low leverage. This financial stability reduces bankruptcy risk and supports ongoing pipeline development.
Bearish
- Extremely high valuation with PS ratio of 568.9: The price-to-sales ratio is 568.9, implying the market expects massive future revenue growth. Even with the acquisition, current sales are minimal, and the valuation leaves little room for error if growth disappoints.
- Deeply unprofitable with negative margins: Crinetics reported a net loss of $127.8 million in Q1 2026, with a net margin of -1,191%. Operating expenses, especially R&D at $100.1 million, continue to drive significant losses, and profitability is not expected in the near term.
- Limited upside to analyst targets: The average analyst target is $85.50, only 0.96% above the current price, and the high target is $90.00, implying just 6.3% upside. With the stock trading near the acquisition price, potential gains are capped unless the deal is renegotiated or new catalysts emerge.
- Acquisition risk and deal completion uncertainty: The acquisition by Vertex is subject to regulatory approvals and shareholder votes. Any delays or antitrust issues could create volatility, and if the deal falls through, the stock could drop significantly toward its pre-announcement levels.
CRNX Technical Analysis
Crinetics' stock has exhibited a dramatic uptrend over the past year, with a 1-year price change of +188.06%, far outpacing the S&P 500's +20.48% gain. The current price of $84.69 sits at 99.9% of its 52-week range (low: $29.63, high: $84.795), indicating the stock is trading near its all-time highs, reflecting strong momentum and investor optimism following the acquisition news. The stock's beta of 0.088 suggests it is significantly less volatile than the broader market, which is unusual for a biotech and may reflect the stability expected from the pending acquisition.
Beta
0.09
0.09x market volatility
Max Drawdown
-42.2%
Largest decline past year
52-Week Range
$30-$85
Price range past year
Annual Return
+188.1%
Cumulative gain past year
| Period | CRNX Return | S&P 500 |
|---|---|---|
| 1m | +1.2% | +3.6% |
| 3m | +130.1% | +2.7% |
| 6m | +95.0% | +11.4% |
| 1y | +188.1% | +18.7% |
| ytd | +81.2% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRNX Fundamental Analysis
Crinetics' revenue has grown significantly, with Q1 2026 revenue of $10.734 million, a 28.73% year-over-year increase, driven by product sales of Palsonify, which contributed $10.306 million, while license and service revenue added $0.428 million. The company remains deeply unprofitable, with a net loss of $127.845 million in Q1 2026, translating to an EPS of -$1.23, and a negative net margin of -1,191.03% (based on quarterly data). Gross margin is high at 98.14%, reflecting the low cost of goods for its oral drug, but operating expenses, particularly R&D of $100.081 million, continue to drive significant operating losses. The balance sheet is solid with a current ratio of 12.32 and a debt-to-equity ratio of 0.049, indicating minimal leverage, but the company is burning cash with a free cash flow of -$125.523 million in Q1 2026, though it raised $389.875 million from stock issuance, providing ample runway for ongoing operations and pipeline development.
Quarterly Revenue
$10734000.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
98.1%
Latest Quarter
Free Cash Flow
$-419516000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRNX Overvalued?
Given Crinetics' negative net income and EBITDA, the most appropriate valuation metric is the price-to-sales (PS) ratio, which stands at 568.91 (trailing), reflecting the market's high expectations for future revenue growth despite minimal current sales. The forward PE is -20.93, which is not meaningful due to expected losses, but the EV/Sales ratio of 185.60 further underscores the premium valuation. Compared to the industry average PS ratio (not provided), Crinetics trades at a substantial premium, justified by its commercial product and promising pipeline, but the valuation implies aggressive growth assumptions. Historically, the PS ratio has ranged from 323.17 to 27,440.94 over the past few years, and the current level of 568.91 is below the historical median, suggesting that despite the recent surge, the stock is not at its most extreme valuation, though it remains elevated relative to its revenue base.
PE
-9.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-9.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. Crinetics is deeply unprofitable, with a net loss of $127.8 million in Q1 2026 and negative free cash flow of $125.5 million. The company's high cash burn rate, despite a recent equity raise of $389.9 million, means it will need continued funding or the acquisition to provide financial stability. Revenue concentration is also a risk, as Palsonify accounts for nearly all sales, and any commercial setbacks could severely impact the top line. The negative net margin of -1,191% underscores the lack of profitability, and the company's reliance on R&D spending for growth creates ongoing earnings volatility.